These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26066338)

  • 1. N-Acetylcysteine Augmentation in Children and Adolescents Diagnosed With Treatment-Resistant Obsessive-Compulsive Disorder: Case Series.
    Yazici KU; Percinel I
    J Clin Psychopharmacol; 2015 Aug; 35(4):486-9. PubMed ID: 26066338
    [No Abstract]   [Full Text] [Related]  

  • 2. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
    Afshar H; Roohafza H; Mohammad-Beigi H; Haghighi M; Jahangard L; Shokouh P; Sadeghi M; Hafezian H
    J Clin Psychopharmacol; 2012 Dec; 32(6):797-803. PubMed ID: 23131885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder.
    Fitzgerald KD; Stewart CM; Tawile V; Rosenberg DR
    J Child Adolesc Psychopharmacol; 1999; 9(2):115-23. PubMed ID: 10461822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
    Potenza MN; Wasylink S; Longhurst JG; Epperson CN; McDougle CJ
    J Clin Psychopharmacol; 1998 Oct; 18(5):423-4. PubMed ID: 9790164
    [No Abstract]   [Full Text] [Related]  

  • 5. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder.
    Sarkar R; Klein J; Krüger S
    Psychopharmacology (Berl); 2008 May; 197(4):687-8. PubMed ID: 18264798
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
    J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a six-month follow-up case series.
    Dell'Osso B; Mundo E; Altamura AC
    CNS Spectr; 2006 Nov; 11(11):879-83; quiz 885. PubMed ID: 17075559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder.
    Storch EA; Lehmkuhl H; Geffken GR; Touchton A; Murphy TK
    Depress Anxiety; 2008; 25(2):172-4. PubMed ID: 17340610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder.
    Fontenelle LF; Mendlowicz MV; Miguel EC; Versiani M
    World J Biol Psychiatry; 2005; 6(1):57-9. PubMed ID: 16097406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
    Dwivedi S; Pavuluri M; Heidenreich J; Wright T
    J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
    [No Abstract]   [Full Text] [Related]  

  • 11. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
    Francobandiera G
    Can J Psychiatry; 2001 May; 46(4):356-8. PubMed ID: 11387793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine augmentation of sertraline in obsessive-compulsive disorder.
    Francobandiera G
    J Clin Psychiatry; 2002 Nov; 63(11):1046-7. PubMed ID: 12469688
    [No Abstract]   [Full Text] [Related]  

  • 13. Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder.
    Owley T; Owley S; Leventhal B; Cook EH
    J Child Adolesc Psychopharmacol; 2002; 12(2):165-71. PubMed ID: 12188985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
    Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Acetylcysteine augmentation in refractory obsessive–compulsive disorder.
    Bhaskara S
    J Psychiatry Neurosci; 2019 May; 44(3):215-216. PubMed ID: 31038300
    [No Abstract]   [Full Text] [Related]  

  • 16. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
    Sun TF; Lin PY; Wu CK
    Chang Gung Med J; 2001 Sep; 24(9):587-92. PubMed ID: 11725630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder.
    Carollo M; Carollo N; Montan G
    CNS Neurosci Ther; 2024 Feb; 30(2):e14653. PubMed ID: 38385640
    [No Abstract]   [Full Text] [Related]  

  • 19. Vortioxetine and Aripiprazole Combination in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Report.
    De Berardis D; Olivieri L; Nappi F; Rapini G; Vellante F; Matarazzo I; Serroni N; Di Giannantonio M
    J Clin Psychopharmacol; 2017 Dec; 37(6):732-734. PubMed ID: 29040153
    [No Abstract]   [Full Text] [Related]  

  • 20. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Mohr N; Vythilingum B; Emsley RA; Stein DJ
    Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.